Movement Alert｜BIOCYTOGEN-B Rises 5.68% in Regular Trading, H1 Net Profit Expected to Surge Over 4x Amid Continued Institutional Accumulation

Market Focus08-11 10:37

On August 11, BIOCYTOGEN-B rose 5.68% in regular trading, trading at HKD 72.95/share, with turnover of HKD 72.43 million. The rally was driven by the company's recently released H1 earnings forecast and sustained institutional buying.

According to the company's profit alert, BIOCYTOGEN-B expects H1 revenue of RMB 936-946 million, representing 51%-52% year-on-year growth, while net profit attributable to shareholders is projected at RMB 236-246 million, a surge of 392%-413% year-on-year from RMB 48 million in the prior-year period. This follows a strong Q1 in which the company posted attributable profit of RMB 104 million on revenue of RMB 433 million, up 74% year-on-year.

Institutional capital continues to flow in, with E Fund Management raising its long position to 10.0% and Fullgoal Fund increasing its stake to 8.23% following a purchase of 556,500 shares at approximately HKD 51.81 per share on July 29. The company's dual-engine growth model — combining humanized model animals (BioMice) and antibody development (RenBiologics) — is further bolstered by a global bispecific ADC strategic partnership with Whitehawk Therapeutics, accelerating scalable profitability.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment